IQCH

Across TCGA pan-cancer cohorts, IQCH Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IQCH data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IQCH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IQCH expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and COAD are the cancer types where IQCH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.051	0.783	<.001	36	view →
UCEC	DFS	Median	All	0.789	0.629	.003	34	view →
COAD	OS	Median	All	0.439	0.809	<.001	31	view →
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	19	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IQCH–LIHC (OS)

Open the LIHC breakdown →